Dynamic Contrast-enhanced CT in Patients Treated with Sorafenib and Erlotinib for Non-small Cell Lung Cancer: a New Method of Monitoring Treatment?

Overview

Journal Eur Radiol

Specialty Radiology

Date 2010 Jul 14

PMID 20625738

Citations 32

Authors

Joline S W Lind

Martijn R Meijerink

Anne-Marie C Dingemans

Cornelis van Kuijk

Michel C Ollers

Dirk De Ruysscher

Pieter E Postmus

Egbert F Smit

Affiliations

Soon will be listed here.

Abstract

Objective: We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome.

Methods: DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed.

Results: Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (p < 0.001) and 9.4 ml/100 g/min at week 6 (p < 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min, p = 0.03) and week 6 (0 versus 13.4 ml/100 g/min, p = 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months, p = 0.06).

Conclusion: Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.

Citing Articles

DCE-CT parameters as new functional imaging biomarkers at baseline and during immune checkpoint inhibitor therapy in patients with lung cancer - a feasibility study.

Brun Andersen M, Drljevic-Nielsen A, Ehlers J, Thorup K, Baandrup A, Palne M Cancer Imaging. 2024; 24(1):105.

PMID: 39135095 PMC: 11320886. DOI: 10.1186/s40644-024-00745-0.

Can spectral computed tomography (CT) replace perfusion CT to assess the histological classification of non-small cell lung cancer?.

Deng L, Yang J, Ren T, Jing M, Han T, Zhang B Quant Imaging Med Surg. 2023; 13(8):4960-4972.

PMID: 37581057 PMC: 10423375. DOI: 10.21037/qims-22-1206.

Preoperative Helical Dynamic Enhanced Multidetector Row Computed Tomography: Can It Be a Prognostic Indicator in Early-Stage Non-small Cell Lung Cancer?.

Moon J, Yi C, Lee K, Woo S, Kwon O, Yang E J Comput Assist Tomogr. 2022; 46(2):308-314.

PMID: 35297586 PMC: 8929303. DOI: 10.1097/RCT.0000000000001270.

A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC.

Aya F, Benegas M, Vinolas N, Reyes R, Vollmer I, Arcocha A Cancers (Basel). 2021; 13(21).

PMID: 34771728 PMC: 8583202. DOI: 10.3390/cancers13215566.

Dual-input tracer kinetic modeling of dynamic contrast-enhanced MRI in thoracic malignancies.

Lee S, Rimner A, Deasy J, Hunt M, Tyagi N J Appl Clin Med Phys. 2019; 20(11):169-188.

PMID: 31602789 PMC: 6839367. DOI: 10.1002/acm2.12740.

References

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Meijerink M, van Cruijsen H, Hoekman K, Kater M, van Schaik C, van Waesberghe J . The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol. 2006; 17(7):1700-13. DOI: 10.1007/s00330-006-0425-9. View

Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

Kamena A, Streitparth F, Grieser C, Lehmkuhl L, Jamil B, Wojtal K . Dynamic perfusion CT: optimizing the temporal resolution for the calculation of perfusion CT parameters in stroke patients. Eur J Radiol. 2007; 64(1):111-8. DOI: 10.1016/j.ejrad.2007.02.025. View

Ng Q, Goh V, Milner J, Stratford M, Folkes L, Tozer G . Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol. 2007; 8(2):111-8. DOI: 10.1016/S1470-2045(07)70001-3. View

Ng Q, Goh V, Klotz E, Fichte H, Saunders M, Hoskin P . Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage?. AJR Am J Roentgenol. 2006; 187(4):1079-84. DOI: 10.2214/AJR.05.0889. View

Thomas J, Arzoomanian R, Alberti D, Marnocha R, Lee F, Friedl A . Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003; 21(2):223-31. DOI: 10.1200/JCO.2003.12.120. View

Koukourakis M, Mavanis I, Kouklakis G, Pitiakoudis M, Minopoulos G, Manolas C . Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol. 2007; 30(3):315-8. DOI: 10.1097/01.coc.0000258119.90805.ca. View

Kiessling F, Boese J, Corvinus C, Ederle J, Zuna I, Schoenberg S . Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring?. Eur Radiol. 2004; 14(7):1226-33. DOI: 10.1007/s00330-004-2288-2. View

10.

Goh V, Liaw J, Bartram C, Halligan S . Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. AJR Am J Roentgenol. 2008; 191(6):W288-92. DOI: 10.2214/AJR.07.3985. View

11.

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View

12.

Wang J, Wu N, Cham M, Song Y . Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009; 193(4):1090-6. DOI: 10.2214/AJR.08.1367. View

13.

Tsushima Y, Funabasama S, Aoki J, Sanada S, Endo K . Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol. 2004; 11(2):215-23. DOI: 10.1016/s1076-6332(03)00578-6. View

14.

Tateishi U, Nishihara H, Watanabe S, Morikawa T, Abe K, Miyasaka K . Tumor angiogenesis and dynamic CT in lung adenocarcinoma: radiologic-pathologic correlation. J Comput Assist Tomogr. 2001; 25(1):23-7. DOI: 10.1097/00004728-200101000-00004. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Therasse P . Measuring the clinical response. What does it mean?. Eur J Cancer. 2002; 38(14):1817-23. DOI: 10.1016/s0959-8049(02)00182-x. View

17.

Kloska S, Fischer T, Sauerland C, Buerke B, Dziewas R, Fischbach R . Increasing sampling interval in cerebral perfusion CT: limitation for the maximum slope model. Acad Radiol. 2009; 17(1):61-6. DOI: 10.1016/j.acra.2009.07.009. View

18.

Stamm G, Nagel H . [CT-expo--a novel program for dose evaluation in CT]. Rofo. 2002; 174(12):1570-6. DOI: 10.1055/s-2002-35937. View

19.

Xiong H, Herbst R, Faria S, Scholz C, Davis D, Jackson E . A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004; 22(4):459-66. DOI: 10.1023/B:DRUG.0000036688.96453.8d. View

20.

Tsushima Y, Funabasama S, Sanada S, Aoki J, Endo K . Development of perfusion CT software for personal computers. Acad Radiol. 2002; 9(8):922-6. DOI: 10.1016/s1076-6332(03)80462-2. View